Accelerator Life Science Partners

Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative parenteral medical countermeasure drugs, particularly tezampanel, for treating seizures and brain injuries. Founded in 2016, the company has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving exposure to soman, a highly toxic chemical weapon. By targeting the central nervous system, Proniras aims to develop novel small-molecule therapeutics for various neurological conditions characterized by high unmet medical needs. Their research is designed to provide medical researchers with valuable tools for advancing treatments in this critical area.

Automera is a biotechnology company specializing in the development of innovative therapeutic methods for drug discovery. The firm focuses on creating autophagy-targeting drugs designed to address specific diseases. Utilizing advanced computational chemistry, artificial intelligence, and quantum molecular dynamics, Automera's technology enables the design of chimeric small molecules that can simultaneously bind to autophagy pathways and selected disease targets. This approach acts as a natural defense mechanism against viruses and bacteria, allowing for the identification and development of effective drugs that harness the body's own systems to combat diseases.

KayoThera is a biotechnology company focused on developing innovative therapeutics aimed at treating late-stage and metastatic cancers. Founded in 2019 and based in Princeton, New Jersey, the company specializes in creating first-in-class immuno- and targeted therapies. Its primary approach involves inhibiting a key enzyme that protects cancer cells and depleting regulatory T-cells, which enhances the effectiveness of existing chemotherapy and immunotherapy treatments. KayoThera's mission is to provide new hope for patients facing previously incurable cancers by advancing its therapeutic programs.

KayoThera is a biotechnology company focused on developing innovative therapeutics aimed at treating late-stage and metastatic cancers. Founded in 2019 and based in Princeton, New Jersey, the company specializes in creating first-in-class immuno- and targeted therapies. Its primary approach involves inhibiting a key enzyme that protects cancer cells and depleting regulatory T-cells, which enhances the effectiveness of existing chemotherapy and immunotherapy treatments. KayoThera's mission is to provide new hope for patients facing previously incurable cancers by advancing its therapeutic programs.

Lydian Neurosciences focusses on developing small molecules for the treatment of sleep disorders.

Rodeo Therapeutics Corp. is a Seattle-based drug development company that focuses on creating novel small molecule therapies aimed at tissue repair and regeneration. Founded in 2017, the company targets specific biological pathways and enzyme mechanisms critical for healing. Its primary objectives include developing treatments for inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Rodeo's innovative approach involves increasing tissue levels of prostaglandin PGE2 by inhibiting the enzyme 15-PGDH, which has shown promise in protecting against colitis and promoting liver regeneration in various animal models. This research positions Rodeo Therapeutics to contribute significantly to the medical management of these conditions.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Coba Therapeutics is a developer of novel therapeutics designed to help in the treatment of metabolic diseases.

Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative parenteral medical countermeasure drugs, particularly tezampanel, for treating seizures and brain injuries. Founded in 2016, the company has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving exposure to soman, a highly toxic chemical weapon. By targeting the central nervous system, Proniras aims to develop novel small-molecule therapeutics for various neurological conditions characterized by high unmet medical needs. Their research is designed to provide medical researchers with valuable tools for advancing treatments in this critical area.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.